我国高血压控制率现状及未来之路的思考

Current status of hypertension control rate in China and reflections on the future path

摘要

本文阐述我国高血压控制率的现状，指出我国高血压控制率水平较低，低于世界控制率平均水平，更低于发达国家高血压控制率。鉴于此，提出了提高高血压控制率的科学对策，特别要重视应用单片复方制剂（SPC）治疗高血压的方法和推广个体化治疗高血压的措施。目前，提高高血压控制率面临着挑战，但也是提高控制率的机遇。认真贯彻《“健康中国 2030”规划纲要》，推广提高血压控制率的科学措施、建立规范化的高血压管理模式，对提高高血压控制率有重要的意义。

Abstract

This article elaborates on the current status of hypertension control rates in China. It points out that the level of hypertension control in China remains relatively low, falling below the global average and even further behind that of developed countries. In light of this, scientific strategies to improve hypertension control rates are proposed, with particular emphasis on the application of single-pill combination (SPC) therapy and the promotion of individualized treatment approaches. Currently, enhancing hypertension control rates presents both challenges and opportunities. Implementing the “Healthy China 2030” initiative, promoting scientific measures to improve blood pressure control and establishing standardized hypertension management models are of great significance for enhancing hypertension control rates.

关键词

高血压 / 控制率 / 现状 / 对策

Key words

hypertension / control rate / current status / strategies

参考文献

[1] Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012—2015[J]. Circulation, 2018, 137(22): 2344-2356.

[2] 中国心血管健康与疾病报告编写组 . 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志, 2021, 36(6): 521-545.

[3] Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2017, 10: S0735-1097.

[4] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure[J]. Hypertension, 2003, 42(6): 1206-1252.

[5] NCD Risk Factor Collaboration (NCD—RisC) . Long—term and recent trends in hypertension awareness, treatment, and control in 12 high—income countries: an analysis of 123 nationally representative surveys[J]. Lancet, 2019, 394(10199): 639-651.

[6] Leung AA, Williams JVA, McAlister FA, et al. Hypertension Canada's Research and Evaluation Committee. Worsening hypertension awareness, treatment, and control rates in Canadian women between 2007 and 2017[J]. Can J Cardiol, 2020, 36(5): 732-739.

[7] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等 . 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 1-46.

[8] 国家心脏中心 . 中国心血管病报告2017[M]. 北京: 中国大百科全书出版社, 2017: 12.

[9] 赵连友, 李妍 . 重视单片复方制剂治疗高血压的临床应用[J]. 中华高血压杂志, 2021, 29(7): 601-604.

[10] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2018, 71(19): e127-e248.

[11] 赵连友 . 重视个体化联合用药治疗高血压的临床价值[J]. 中国实用内科杂志, 2019, 39(1): 1-4.

[12] 国家心血管病中心 . 中国心血管健康与疾病报告2023[M]. 北京: 中国协和医科大学出版社, 2024: 5.

[13] 中国成人血脂异常防治指南修订委员会 . 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-953.

[14] 新华社 . 中共中央国务院印发《“健康中国2030”规划纲要》[J]. 中华人民共和国国务院公报, 2016(32): 5-20.

[15] 刘小立, 彭绩, 周海滨, 等 . 深圳市慢性非传染性疾病及其相关危险因素流行病学研究[M]. 北京: 人民卫生出版社, 2009: 256-257.

[16] 周文岳, 李松涛, 刘灿磊, 等 . 浙江省玉环县35岁以上人群高血压流行病学调查[J]. 中国预防医学杂志, 2011, 12(5): 431-433.